Philips Stellarex Clinical Summary: Illuminate Pivotal Randomized Trial

Stellarex is the only DCB reported to have durable patency at 2 years in severely calcified lesions

Stellarex demonstrates a robust treatment effect over PTA in severely calcified lesions

82% of the severely calcified segments were greater than 50% of the total lesion length